{"id":"cefotiam-hexetil","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["cefotiam hexetil","cefotiam hexetil hydrochloride","cefotiam hexetil HCl"],"offLabel":[],"synonyms":["cefotiam hexetil","cefotiam hexetil hydrochloride","cefotiam hexetil HCl"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like buildings, and the bacteria are like construction workers. Cefotiam hexetil stops the bacteria from building their walls, which are essential for their survival, effectively killing them.","oneSentence":"Cefotiam hexetil works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Cefotiam hexetil is a second-generation cephalosporin antibiotic that exerts its antibacterial effects by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall, thereby inhibiting the cross-linking of peptidoglycan and ultimately leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/549","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cefotiam hexetil","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:20:30.873381","biosimilars":[],"competitors":[],"genericName":"cefotiam hexetil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"J92A81Y99T","CHEBI":"CHEBI:59211","UMLSCUI":"C0081958","ChEMBL_ID":"CHEMBL1200589","KEGG_DRUG":"D01415","PUBCHEM_CID":"125846","SNOMEDCT_US":"734643008","SECONDARY_CAS_RN":"95789-30-3","MESH_SUPPLEMENTAL_RECORD_UI":"C067049"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":21,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"cefotiam hexetil","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Cefotiam hexetil is a small molecule antibiotic originally developed by, but its current ownership is unknown. It is used to treat bacterial infections, although its specific target and approved indications are not well-documented. The commercial status of cefotiam hexetil is unclear, as it is unknown whether it is patented or available as a generic medication. Further research is needed to determine its key safety considerations and pharmacokinetic properties. Overall, cefotiam hexetil is an antibiotic with potential therapeutic applications, but its development and use are not well-established.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}